Levetiracetam for managing neurologic and psychiatric disorders

American Journal of Health-System Pharmacy

Volumn 66, Issue 6, 2009, Pages 541-561

  Farooq, Muhammad U ^a,b   Bhatt, Archit ^a   Majid, Arshad ^a   Gupta, Rishi ^b   Khasnis, Atul ^c   Kassab, Mounzer Y ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b East Lansing   (United States)

^c NONE

Author keywords

Anticonvulsants; Epilepsy; Levetiracetam; Mechanism of action; Mental disorders; Nervous system diseases; Toxicity

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE RECEPTOR; CARBAMAZEPINE; CYTOCHROME P450 ISOENZYME; DIGOXIN; ETIRACETAM; GLYCINE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PLACEBO; SEDATIVE AGENT; VALPROIC ACID; WARFARIN; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; PIRACETAM;

ACCIDENTAL INJURY; ADD ON THERAPY; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANTICONVULSANT ACTIVITY; ANXIETY; ANXIETY DISORDER; ASTHENIA; ATAXIA; AUTISM; AUTOMUTILATION; BACKACHE; BEHAVIOR DISORDER; BIPOLAR DISORDER; CHILD; CLINICAL TRIAL; COGNITIVE DEFECT; COMPLEX PARTIAL SEIZURE; CONFUSION; CONVULSION; DEPERSONALIZATION; DEPRESSION; DISTRESS SYNDROME; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DROWSINESS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG PROTEIN BINDING; DYSKINESIA; DYSTONIA; EPILEPSY; EPILEPTIC STATE; FATIGUE; FLU LIKE SYNDROME; FOCAL EPILEPSY; GILLES DE LA TOURETTE SYNDROME; GRAND MAL EPILEPSY; HALLUCINATION; HEADACHE; HOSTILITY; HUMAN; HUNTINGTON CHOREA; HYPERACTIVITY; IMPULSIVENESS; INFECTION; INSOMNIA; IRRITABILITY; MANIA; MENTAL DISEASE; MENTAL INSTABILITY; MONOTHERAPY; MOOD DISORDER; MULTIPLE SCLEROSIS; MYOCLONUS EPILEPSY; NAUSEA; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPATHIC PAIN; PANIC; PARKINSON DISEASE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; REVIEW; RHINITIS; SEDATION; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; SPASTICITY; SUICIDAL IDEATION; TARDIVE DYSKINESIA; TREMOR; URINARY TRACT INFECTION; URINE INCONTINENCE; WEIGHT GAIN; WEIGHT REDUCTION;

ANTICONVULSANTS; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; PIRACETAM;

EID: 67650107605     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070607     Document Type: Review

References (109)

1. Shorvon S. Pyrrolidone derivatives. Lancet. 2001; 358:1885-1892
2. Klitgaard H, Pitkanen A. Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord. 2003; 5(suppl 1):S9-16. (Pubitemid 36818439)
3. Ji-qun C, Ishihara K, Nagayama T et al. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs. Epilepsia. 2005; 46:1362-1370
4. Lambeng N, Grossmann M, Chatelain P et al. Solubilization and immunopurification of rat brain synaptic vesicle protein 2A with maintained binding properties. Neurosci Lett. 2006; 398:107-12.
5. Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol. 2006; 536:102-108
6. Marini H, Costa C, Passaniti M et al. Levetiracetam protects against kainic acid-induced toxicity. Life Sci. 2004; 74:1253-1264 (Pubitemid 38022063)
7. Kerrigan JF, Ng YT, Chung S et al. The hypothalamic hamartoma: a model of subcortical epileptogenesis and encephalopathy. Semin Pediatr Neurol. 2005; 12:119-131 (Pubitemid 40967990)
8. Morrell F. Varieties of human secondary epileptogenesis. J Clin Neurophysiol. 1989; 6:227-275 (Pubitemid 19184241)
9. Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther. 1998; 284:474-479 (Pubitemid 28086631)
10. Husum H, Bolwig TG, Sanchez C et al. Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling: implications for antiepileptogenic and mood-stabilizing properties. Epilepsy Behav. 2004; 5:204-215
11. Carunchio I, Pieri M, Ciotti MT et al. Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. Epilepsia. 2007; 48:654-662
12. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000; 85:77-85.
13. Ramael S, Daoust A, Otoul C et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia. 2006; 47:1128-1135 (Pubitemid 44086747)
14. Ramael S, De Smedt F, Toublanc N et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther. 2006; 28:734-744
15. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004; 43:707-724
16. Patsalos PN. The pharmacokinetic characteristics of levetiracetam. Methods Find Exp Clin Pharmacol. 2003; 25:123-9.
17. French J. Use of levetiracetam in special populations. Epilepsia. 2001; 42(suppl 4):40-43
18. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia. 2000; 41:1276-1283
19. Cereghino JJ, Biton V, Abou-Khalil B et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000; 55:236-242 (Pubitemid 30604624)
20. Shorvon SD, Lowenthal A, Janz D et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia. 2000; 41:1179-1186
21. Morrell MJ, Leppik I, French J et al. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res. 2003; 54:153-161 (Pubitemid 36776733)
22. Glauser TA, Ayala R, Elterman RD et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology. 2006; 66:1654-1660
23. Verdru P, Wajgt A, Schiemann DJ et al. Efficacy and safety of levetiracetam 3000 mg/d as adjunctive treatment in adolescents and adults suffering from idiopathic generalised epilepsy with myoclonic seizures. Epilepsia. 2005; 46(suppl 6):54-55 Abstract 028.
24. Berkovic SF, Knowlton RC, Leroy RF et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology. 2007; 69:1751-1760
25. Brodie MJ, Perucca E, Ryvlin P et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007; 68:402-408
26. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure. 2000; 9:80-87
27. Steinhoff BJ, Somerville ER, Van Paesschen W et al. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Epilepsy Res. 2007; 76:6-14. (Pubitemid 47243697)
28. Striano P, Coppola A, Pezzella M et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology. 2007; 69:250-254 (Pubitemid 47205686)
29. Verrotti A, Cerminara C, Coppola G et al. Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents. Dev Med Child Neurol. 2008; 50:29-32.
30. Rupprecht S, Franke K, Fitzek S et al. Levetiracetam as a treatment option in non-convulsive status epilepticus. Epilepsy Res. 2007; 73:238-244 (Pubitemid 46304172)
31. Farooq MU, Naravetla B, Majid A et al. IV levetiracetam in the management of non-convulsive status epilepticus. Neurocrit Care. 2007; 7:36-39 (Pubitemid 350242677)
32. Romanelli MF, Morris JC, Ashkin K et al. Advanced Alzheimer's disease is a risk factor for late-onset seizures. Arch Neurol. 1990; 47:847-850
33. Amatniek JC, Hauser WA, DelCastillo-Castaneda C et al. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia. 2006; 47:867-872
34. Belcastro V, Costa C, Galletti F et al. Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. Eur J Neurol. 2007; 14:1176-1178 (Pubitemid 47459735)
35. Cramer JA, Leppik IE, Rue KD et al. Tolerability of levetiracetam in elderly patients with CNS disorders. Epilepsy Res. 2003; 56:135-145 (Pubitemid 37474114)
36. Cramer JA, Van Hammee G. Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. Epilepsy Behav. 2003; 4:118-123 (Pubitemid 37184582)
37. Krauss GL, Bergin A, Kramer RE et al. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology. 2001; 56:411-412
38. Frucht SJ, Louis ED, Chuang C et al. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology. 2001; 57:1112-1114 (Pubitemid 32880216)
39. Ferrendelli JA, French J, Leppik I et al. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav. 2003; 4:702-709 (Pubitemid 38035693)
40. Magaudda A, Gelisse P, Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia. 2004; 45:678-681 (Pubitemid 38802198)
41. Patel NC, Landan IR, Levin J et al. The use of levetiracetam in refractory status epilepticus. Seizure. 2006; 15:137-141
42. Mula M, Sander JW, Trimble MR. The role of hippocampal sclerosis in antiepileptic drug-related depression in patients with epilepsy: a study on levetiracetam. Seizure. 2006; 15:405-408 (Pubitemid 44184813)
43. Hill MP, Brotchie JM, Crossman AR et al. Levetiracetam interferes with the L-dopa priming process in MPTP-lesioned drug-naive marmosets. Clin Neuropharmacol. 2004; 27:171-177
44. Margineanu DG, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res. 2000; 42:281-285 (Pubitemid 30743409)
45. Bezard E, Hill MP, Crossman AR et al. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol. 2004; 485:159-164 (Pubitemid 38134410)
46. Tousi B, Subramanian T. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease. Parkinsonism Relat Disord. 2005; 11:333-334 (Pubitemid 40982511)
47. Hill MP, Ravenscroft P, Bezard E et al. Levetiracetam potentiates the anti-dyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J Pharmacol Exp Ther. 2004; 310:386-394
48. Zesiewicz TA, Sullivan KL, Maldonado JL et al. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord. 2005; 20:1205-1209
49. Meco G, Fabrizio E, Epifanio A et al. Levetiracetam in L-dopa-induced dyskinesia. Clin Neuropharmacol. 2005; 28:102-103
50. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002; 43:9-18. (Pubitemid 34215447)
51. Zesiewicz TA, Sullivan KL, Hauser RA et al. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. Mov Disord. 2006; 21:1998-2001.
52. De Tommaso M, Di Fruscolo O, Sciruicchio V et al. Efficacy of levetiracetam in Huntington disease. Clin Neuropharmacol. 2005; 28:280-284
53. Zesiewicz TA, Sanchez-Ramos J, Sullivan KL et al. Levetiracetam-induced parkinsonism in a Huntington disease patient. Clin Neuropharmacol. 2005; 28:188-190 (Pubitemid 41134247)
54. Klitgaard H, Matagne A, Grimee R et al. Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy. Seizure. 2003; 12:92-100. (Pubitemid 36284982)
55. Konitsiotis S, Pappa S, Mantas C et al. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord. 2006; 21:1219-1221 (Pubitemid 44336612)
56. Meco G, Fabrizio E, Epifanio A et al. Levetiracetam in tardive dyskinesia. Clin Neuropharmacol. 2006; 29:265-268
57. Bona JR. Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series. J Clin Psychopharmacol. 2006; 26:215-216
58. McGavin CL, John V, Musser WS. Levetiracetam as a treatment for tardive dyskinesia: a case report. Neurology. 2003; 61:419. (Pubitemid 36975985)
59. Tarsy D, Ryan RK, Ro SI. An open-label trial of levetiracetam for treatment of cervical dystonia. Mov Disord. 2006; 21:734-735 (Pubitemid 43792769)
60. Hering S, Wenning GK, Seppi K et al. An open trial of levetiracetam for segmental and generalized dystonia. Mov Disord. 2007; 22:1649-1651 (Pubitemid 47477932)
61. Sullivan KL, Hauser RA, Louis ED et al. Levetiracetam for the treatment of generalized dystonia. Parkinsonism Relat Disord. 2005; 11:469-471
62. Yardimci N, Karatas M, Kilinc M et al. Levetiracetam in Meige's syndrome. Acta Neurol Scand. 2006; 114:63-66
63. Zesiewicz TA, Louis ED, Sullivan KL et al. Substantial improvement in a Meige's syndrome patient with levetiracetam treatment. Mov Disord. 2004; 19:1518-1521
64. Alusi SH, Worthington J, Glickman S et al. A study of tremor in multiple sclerosis. Brain. 2001; 124:720-730
65. Sechi GP, Zuddas M, Piredda M et al. Treatment of cerebellar tremors with carbamazepine: a controlled trial with long-term follow-up. Neurology. 1989; 39:1113-1115 (Pubitemid 19217487)
66. Sechi G, Agnetti V, Sulas FM et al. Effects of topiramate in patients with cerebellar tremor. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27:1023-1027 (Pubitemid 37141391)
67. Striano P, Coppola A, Vacca G et al. Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study. J Neurol 2006; 253:762-766 (Pubitemid 43980148)
68. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett. 2001; 306:5-8.
69. Rigo JM, Hans G, Nguyen L et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol. 2002; 136:659-672 (Pubitemid 34785708)
70. Hawker K, Frohman E, Racke M. Levetiracetam for phasic spasticity in multiple sclerosis. Arch Neurol. 2003; 60:1772-1774 (Pubitemid 37521635)
71. Pakalnis A, Kring D, Meier L. Levetiracetam prophylaxis in pediatric migraine - an open-label study. Headache. 2007; 47:427-430 (Pubitemid 46426416)
72. Krusz JC. Levetiracetam as prophylaxis for resistant headaches. Cephalalgia. 2001; 21:373.
73. Drake ME, Greathouse NI, Armentbright AD et al. Levetiracetam for preventive treatment of migraine. Cephalalgia. 2001; 21:368-383
74. Miller GS. Efficacy and safety of levetiracetam in pediatric migraine. Headache. 2004; 44:238-243 (Pubitemid 38436686)
75. Wasserman S, Iyengar R, Chaplin WF et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 2006; 21:363-7. (Pubitemid 44498278)
76. Rugino TA, Samsock TC. Levetiracetam in autistic children: an open-label study. J Dev Behav Pediatr. 2002; 23:225-230
77. Krusz JC. Levetiracetam, given intravenously, to treat refractory migraines. Paper presented at the 14th International Migraine Trust Meeting. September 23-26, 2002.
78. Farooq MU, Majid A, Pysh JJ et al. Role of intravenous levetiracetam in status migrainosus. J Headache Pain. 2007; 8:143-144 (Pubitemid 46796403)
79. Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology. 2002; 59(suppl 2):S14-7.
80. Guay DR. Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain. Am J Geriatr Pharmacother. 2003; 1:18-37. (Pubitemid 40410984)
81. Price MJ. Levetiracetam in the treatment of neuropathic pain: three case studies. Clin J Pain. 2004; 20:33-36 (Pubitemid 38030117)
82. Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure. 2001; 10:287-93. (Pubitemid 32700857)
83. Willmore LJ. Antiepileptic drugs and neuroprotection: current status and future roles. Epilepsy Behav. 2005; 7(suppl 3):S25-8.
84. Pitkanen A, Kubova H. Antiepileptic drugs in neuroprotection. Expert Opin Pharmacother. 2004; 5:777-798
85. Sutula T. Antiepileptic drugs to prevent neural degeneration associated with epilepsy: assessing the prospects for neuroprotection. Epilepsy Res. 2002; 50:125-129 (Pubitemid 34876592)
86. Costa C, Martella G, Picconi B et al. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke. 2006; 37:1319-1326 (Pubitemid 43731883)
87. De Deyn PP, Reuck JD, Deberdt W et al. Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group. Stroke. 1997; 28:2347-2352
88. Muralidharan A, Bhagwagar Z. Potential of levetiracetam in mood disorders: a preliminary review. CNS Drugs. 2006; 20:969-979 (Pubitemid 44912706)
89. Simon NM, Worthington JJ, Doyle AC et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004; 65:1219-1222
90. Papp LA. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. J Clin Psychiatry. 2006; 67:1573-1576
91. Kinrys G, Wygant LE, Pardo TB et al. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry. 2006; 67:211-214 (Pubitemid 43357466)
92. Post RM, Altshuler LL, Frye MA et al. Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. J Clin Psychiatry. 2005; 66:370-374
93. Grunze H, Langosch J, Born C et al. Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J Clin Psychiatry. 2003; 64:781-784 (Pubitemid 36897214)
94. Niespodziany I, Klitgaard H, Margineanu DG. Desynchronizing effect of levetiracetam on epileptiform responses in rat hippocampal slices. Neuroreport. 2003; 14:1273-1276
95. Klitgaard H, Matagne A, Gobert J et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol. 1998; 353:191-206. (Pubitemid 28352266)
96. Strakowski SM, Delbello MP, Adler CM. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol Psychiatry. 2005; 10:105-116 (Pubitemid 40139591)
97. Bersani G. Levetiracetam in bipolar spectrum disorders: first evidence of efficacy in an open, add-on study. Hum Psychopharmacol. 2004; 19:355-356 (Pubitemid 39106879)
98. Kaufman KR. Monotherapy treatment of bipolar disorder with levetiracetam. Epilepsy Behav. 2004; 5:1017-1020 (Pubitemid 40003928)
99. Smith-Hicks CL, Bridges DD, Paynter NP et al. A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Mov Disord. 2007; 22:1764-1770
100. Cramer JA, De Rue K, Devinsky O et al. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav. 2003; 4:124-132 (Pubitemid 37184583)
101. Kossoff EH, Bergey GK, Freeman JM et al. Levetiracetam psychosis in children with epilepsy. Epilepsia. 2001; 42:1611-1613
102. Sirsi D, Safdieh JE. The safety of levetiracetam. Expert Opin Drug Saf. 2007; 6:241-250
103. Youroukos S, Lazopoulou D, Michelakou D et al. Acute psychosis associated with levetiracetam. Epileptic Disord. 2003; 5:117-119
104. White JR, Walczak TS, Leppik IE et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology. 2003; 61:1218-1221
105. Mula M, Trimble MR, Yuen A et al. Psychiatric adverse events during levetiracetam therapy. Neurology. 2003; 61:704-706
106. Nash EM, Sangha KS. Levetiracetam. Am J Health-Syst Pharm. 2001; 58:1195-1199
107. Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia. 2001; 42(suppl 4):24-7.
108. Barrueto F Jr, Williams K, Howland MA et al. A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data. J Toxicol Clin Toxicol. 2002; 40:881-4.
109. ClinicalTrials.gov. Levetiracetam for cramps, spasticity and neuroprotection in motor neuron disease (NCT00324454). www.clinicaltrials.gov/ ct2/show/NCT00324454?term= levetiracetam+for+cramps+spasticity+and+neuroprotection+in+motor+neuron+ disease&rank=1 (accessed 2008 Dec 26).